Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. (THAR) on September 11, 2024. The filing reports the entry into a Material Definitive Agreement and includes Regulation FD disclosure regarding a business presentation.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures for the reporting period. The document focuses on a strategic licensing agreement rather than periodic financial results.
Material Changes and Agreements
On September 11, 2024, Tharimmune entered into a Patent License Agreement with Intract Pharma Limited. Key terms include:
- Licensed Asset: Exclusive global rights (outside South Korea) to develop and commercialize INT-023/TH023, an oral anti-TNF-α monoclonal antibody (infliximab).
- Technology: License to Intract's Soteria® and Phloral® delivery platforms and an existing supply agreement for infliximab.
- Financial Considerations: Intract received an upfront payment. Future payments are contingent on equity financing, development/regulatory/commercial milestones, and mid-single digit royalties on net product sales.
- Options: Tharimmune retains a right of first refusal post-Phase 2 and has an option to license the platform for up to four additional targets.
- Termination: The agreement may be terminated by Tharimmune with 90 days' notice or by either party for material breach or insolvency.
Guidance, Outlook, and Risks
The filing incorporates a business presentation containing forward-looking statements. Management disclaims any obligation to update these statements. The agreement includes standard termination risks related to insolvency, bankruptcy, or material breach. The full text of the agreement will be filed in the Form 10-Q for the quarter ended September 30, 2024.
Investor Verification Checklist
- Verify the exact amount of the upfront payment made to Intract Pharma Limited.
- Review the specific milestones and payment amounts detailed in the full Patent License Agreement (to be filed in the upcoming 10-Q).
- Assess the impact of the equity financing trigger on potential future dilution.
- Confirm the status of the Phase 2 clinical trial timeline referenced in the right of first refusal clause.